Literature DB >> 11084537

[Germ-line mutations of the BRCA1 gene in northeastern France].

J P Fricker1, D Muller, B Cutuli, J F Rodier, J C Janser, G M Jung, R Mors, T Petit, P Haegele, J Abecassis.   

Abstract

Thirty-seven breast/ovarian or breast-only cancer families selected on a regional basis have been analyzed for mutations at BRCA1. By combining direct sequence analysis and protein truncation test, mutations were detected in 14 families (38%). We found seven different mutations, two of which have not been described before. Mutations at BRCA1 were present in 60% of breast/ovarian and 32% of breast-only cancer families. Mutations were frequent in families with at least one breast cancer case before age 40 (44%) and/or one bilateral breast cancer case (54%). Two mutations, namely 3600del11 and G1710X, are frequent in the population native from northeastern France. Oriented BRCA1 analysis should facilitate carrier detection in breast and/or ovarian cancer families stemming from this French area.

Entities:  

Mesh:

Year:  2000        PMID: 11084537

Source DB:  PubMed          Journal:  Bull Cancer        ISSN: 0007-4551            Impact factor:   1.276


  4 in total

1.  BRCA1 testing in breast and/or ovarian cancer families from northeastern France identifies two common mutations with a founder effect.

Authors:  Danièle Muller; Catherine Bonaiti-Pellié; Joseph Abecassis; Dominique Stoppa-Lyonnet; Jean-Pierre Fricker
Journal:  Fam Cancer       Date:  2004       Impact factor: 2.375

2.  Is there a genetic anticipation in breast and/or ovarian cancer families with the germline c.3481_3491del11 mutation?

Authors:  R El Tannouri; E Albuisson; P Jonveaux; E Luporsi
Journal:  Fam Cancer       Date:  2018-01       Impact factor: 2.375

3.  A mutation analysis of the BRCA1 gene in 140 families from southeast France with a history of breast and/or ovarian cancer.

Authors:  Philippe Rostagno; Jeanine Gioanni; Eliane Garino; Pierre Vallino; Moise Namer; Marc Frenay
Journal:  J Hum Genet       Date:  2003-06-24       Impact factor: 3.172

4.  Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria.

Authors:  Juliane Hoyer; Georgia Vasileiou; Steffen Uebe; Marius Wunderle; Cornelia Kraus; Peter A Fasching; Christian T Thiel; Arndt Hartmann; Matthias W Beckmann; Michael P Lux; André Reis
Journal:  BMC Cancer       Date:  2018-09-26       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.